Literature DB >> 21271007

Estimating the cost of treating patients with liver cirrhosis at the Mexican Social Security Institute.

María Esther Quiroz1, Yvonne N Flores, Belkis Aracena, Víctor Granados-García, Jorge Salmerón, Ruth Pérez, Guillermo Cabrera, Roshan Bastani.   

Abstract

OBJECTIVE: To estimate the annual cost of treating patients with cirrhosis at the Mexican Institute of Social Security (IMSS per its abbreviation in Spanish).
MATERIAL AND METHODS: The annual cost of treating three stages of cirrhosis (Child-Pugh A, Child-Pugh B and Child-Pugh C) was estimated using micro-costing techniques and medical experts. These results were compared and contrasted with prices reported by IMSS.
RESULTS: The annual cost of treatment, in USA dollars, by Child-Pugh stage was: a) micro-costing results: $1110.17 stage A, $549.55 stage B and $348.16 stage C; b) opinion of medical experts: $1 633.64, $6564.04 and $19660.35, respectively; and c) IMSS costs: $4269.00, $16949.63 and $30249.25, respectively.
CONCLUSIONS: The cost of treating patients with cirrhosis is considerable, and costs increase as the disease worsens. Cost estimates vary depending on the source of information, and the methodology used. There are discrepancies between the procedures reported in medical records and treatment recommendations by IMSS liver experts.

Entities:  

Mesh:

Year:  2010        PMID: 21271007

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  3 in total

1.  Updates on Hepato-Renal Syndrome.

Authors:  Kyota Fukazawa; H Thomas Lee
Journal:  J Anesth Clin Res       Date:  2013-09-27

2.  Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria.

Authors:  Maria Dimitrova; Kaloyan Pavlov; Konstantin Mitov; Jordan Genov; Guenka Ivanova Petrova
Journal:  Front Med (Lausanne)       Date:  2017-08-07

3.  The Economic Burden of Liver Cirrhosis in Iran: a Cost of Illness Study.

Authors:  Ali Akbari Sari; Ali Kazemi Karyani; Seyed Moayed Alavian; Mohamad Arab; Fateme Rostami Gholmohamadi; Satar Rezaei
Journal:  Iran J Public Health       Date:  2015-04       Impact factor: 1.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.